These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 17465710)
1. Adducin polymorphisms and the treatment of hypertension. Manunta P; Citterio L; Lanzani C; Ferrandi M Pharmacogenomics; 2007 May; 8(5):465-72. PubMed ID: 17465710 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives--the adducin paradigm. Manunta P; Bianchi G J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S30-5. PubMed ID: 16565244 [TBL] [Abstract][Full Text] [Related]
3. Adducin polymorphism: detection and impact on hypertension and related disorders. Bianchi G; Ferrari P; Staessen JA Hypertension; 2005 Mar; 45(3):331-40. PubMed ID: 15699449 [TBL] [Abstract][Full Text] [Related]
4. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach. Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240 [TBL] [Abstract][Full Text] [Related]
5. Genetics of primary hypertension: the clinical impact of adducin polymorphisms. Citterio L; Lanzani C; Manunta P; Bianchi G Biochim Biophys Acta; 2010 Dec; 1802(12):1285-98. PubMed ID: 20382219 [TBL] [Abstract][Full Text] [Related]
6. Role of the adducin family genes in human essential hypertension. Lanzani C; Citterio L; Jankaricova M; Sciarrone MT; Barlassina C; Fattori S; Messaggio E; Serio CD; Zagato L; Cusi D; Hamlyn JM; Stella A; Bianchi G; Manunta P J Hypertens; 2005 Mar; 23(3):543-9. PubMed ID: 15716695 [TBL] [Abstract][Full Text] [Related]
7. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941 [TBL] [Abstract][Full Text] [Related]
8. Alpha Adducin (ADD1) Gene Polymorphism and New Onset of Diabetes Under the Influence of Selective Antihypertensive Therapy in Essential Hypertension. Gupta S; Jhawat V; Agarwal BK; Roy P; Saini V Curr Hypertens Rev; 2019; 15(2):123-134. PubMed ID: 30062972 [TBL] [Abstract][Full Text] [Related]
9. Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats. Tripodi G; Florio M; Ferrandi M; Modica R; Zimdahl H; Hubner N; Ferrari P; Bianchi G Biochem Biophys Res Commun; 2004 Nov; 324(2):562-8. PubMed ID: 15474463 [TBL] [Abstract][Full Text] [Related]
10. A Review of the Epidemiological Evidence for Adducin Family Gene Polymorphisms and Hypertension. Zhang JR; Hu WN; Li CY Cardiol Res Pract; 2019; 2019():7135604. PubMed ID: 31275642 [TBL] [Abstract][Full Text] [Related]
11. Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. Bianchi G Am J Physiol Regul Integr Comp Physiol; 2005 Dec; 289(6):R1536-49. PubMed ID: 16278339 [TBL] [Abstract][Full Text] [Related]
12. Altered expression of renal aquaporins and α-adducin polymorphisms may contribute to the establishment of salt-sensitive hypertension. Procino G; Romano F; Torielli L; Ferrari P; Bianchi G; Svelto M; Valenti G Am J Hypertens; 2011 Jul; 24(7):822-8. PubMed ID: 21451595 [TBL] [Abstract][Full Text] [Related]
13. Adducin and hypertension. Staessen JA; Bianchi G Pharmacogenomics; 2005 Oct; 6(7):665-9. PubMed ID: 16207143 [TBL] [Abstract][Full Text] [Related]
14. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. Psaty BM; Smith NL; Heckbert SR; Vos HL; Lemaitre RN; Reiner AP; Siscovick DS; Bis J; Lumley T; Longstreth WT; Rosendaal FR JAMA; 2002 Apr; 287(13):1680-9. PubMed ID: 11926892 [TBL] [Abstract][Full Text] [Related]
15. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Ferrari P; Ferrandi M; Valentini G; Bianchi G Am J Physiol Regul Integr Comp Physiol; 2006 Mar; 290(3):R529-35. PubMed ID: 16467500 [TBL] [Abstract][Full Text] [Related]
16. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. Ferrari P Biochim Biophys Acta; 2010 Dec; 1802(12):1254-8. PubMed ID: 20083196 [TBL] [Abstract][Full Text] [Related]
17. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain. Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430 [TBL] [Abstract][Full Text] [Related]
18. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies. Ferrandi M; Molinari I; Torielli L; Padoani G; Salardi S; Rastaldi MP; Ferrari P; Bianchi G Sci Transl Med; 2010 Nov; 2(59):59ra86. PubMed ID: 21106940 [TBL] [Abstract][Full Text] [Related]
19. Blocking the salt-inducible kinase 1 network prevents the increases in cell sodium transport caused by a hypertension-linked mutation in human alpha-adducin. Stenström K; Takemori H; Bianchi G; Katz AI; Bertorello AM J Hypertens; 2009 Dec; 27(12):2452-7. PubMed ID: 19657284 [TBL] [Abstract][Full Text] [Related]
20. Intra-erythrocyte cation concentrations in relation to the C1797T beta-adducin polymorphism in a general population. Richart T; Thijs L; Kuznetsova T; Tikhonoff V; Zagato L; Lijnen P; Fagard R; Wang J; Bianchi G; Staessen JA J Hum Hypertens; 2007 May; 21(5):387-92. PubMed ID: 17301826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]